The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies

L. Kerrie(Infinity Pharmaceuticals (United States)), Jeffery L. Kutok(Infinity Pharmaceuticals (United States))

PLoS ONE

August 1, 2018

10.1371/journal.pone.0200725

Cited by 29

Related Papers

HSP90 Inhibition Enhances Antimitotic Drug-Induced Mitotic Arrest and Cell Death in Preclinical Models of Non-Small Cell Lung Cancer

|PLoS ONE|2014|19